- Home
- STOK vs SPH Comparison
STOK vs SPH Comparison
Compare STOK & SPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STOK
- SPH
- Stock Information
- Founded
- STOK 2014
- SPH 1945
- Country
- STOK United States
- SPH United States
- Employees
- STOK N/A
- SPH N/A
- Industry
- STOK Biotechnology: Pharmaceutical Preparations
- SPH Other Specialty Stores
- Sector
- STOK Health Care
- SPH Consumer Discretionary
- Exchange
- STOK Nasdaq
- SPH Nasdaq
- Market Cap
- STOK 1.3B
- SPH 1.2B
- IPO Year
- STOK 2019
- SPH 1996
- Fundamental
- Price
- STOK $23.19
- SPH $18.19
- Analyst Decision
- STOK Strong Buy
- SPH
- Analyst Count
- STOK 9
- SPH 0
- Target Price
- STOK $31.00
- SPH N/A
- AVG Volume (30 Days)
- STOK 1.4M
- SPH 124.3K
- Earning Date
- STOK 11-04-2025
- SPH 11-13-2025
- Dividend Yield
- STOK N/A
- SPH 7.11%
- EPS Growth
- STOK N/A
- SPH N/A
- EPS
- STOK 0.68
- SPH 1.49
- Revenue
- STOK $205,632,000.00
- SPH $1,429,783,000.00
- Revenue This Year
- STOK $416.54
- SPH $10.99
- Revenue Next Year
- STOK N/A
- SPH N/A
- P/E Ratio
- STOK $33.39
- SPH $12.28
- Revenue Growth
- STOK 1128.17
- SPH 6.29
- 52 Week Low
- STOK $5.35
- SPH $16.92
- 52 Week High
- STOK $38.69
- SPH $22.24
- Technical
- Relative Strength Index (RSI)
- STOK 33.50
- SPH 43.31
- Support Level
- STOK $20.32
- SPH $17.68
- Resistance Level
- STOK $33.88
- SPH $18.28
- Average True Range (ATR)
- STOK 2.07
- SPH 0.34
- MACD
- STOK -1.56
- SPH -0.07
- Stochastic Oscillator
- STOK 18.78
- SPH 36.30
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
About SPH Suburban Propane Partners L.P.
Suburban Propane Partners LP distributes propane, fuel oil, and other refined fuels to customers in the East Coast and West Coast regions of the United States. Other operations include natural gas and electricity marketing in the deregulated New York and Pennsylvania markets. The company operates in three segments: Propane; Fuel Oil and Refined Fuels; and Natural Gas and Electricity. It generates maximum revenue from Propane segment.